Human-Derived Regulatory Elements for High Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in achieving high rates of transgene expression in target tissues and are limited by the packaging capacity of vectors, necessitating the development of short regulatory elements that can drive high expression of transgenes effectively.
Innovation Solution
The use of human-derived regulatory elements, such as those listed in TABLE 1, which are operably linked to transgenes to enhance expression levels by 1.5 to 100-fold or more in various cell types, even when linked to large transgenes exceeding 1 kb in size, thereby overcoming vector capacity constraints.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional vectors are used for gene therapy, then transgene expression can be achieved, but the packaging capacity limits the size of transgenes that can be delivered
Solution Approach 1:
The patent extracts and optimizes specific regulatory elements (promoters, enhancers, UTRs, introns) from their original genomic contexts to create compact, high-performance regulatory modules. This allows large transgenes to be delivered by removing unnecessary vector components and retaining only the essential, highly efficient regulatory sequences that drive transgene expression.
Solution Approach 2:
The patent modifies regulatory element parameters including sequence composition, length, and structural characteristics to maximize expression efficiency within limited vector capacity. By optimizing these parameters, the patent achieves high-level transgene expression with minimal regulatory sequence requirements, thereby accommodating larger transgene payloads.
2Productivity
If regulatory elements are extended to drive high transgene expression, then expression levels increase, but the regulatory element length increases beyond vector capacity
Solution Approach 1:
The patent identifies and extracts the most critical functional domains within regulatory elements—such as core promoter regions, key enhancer motifs, and essential UTR sequences—that contribute disproportionately to expression levels. By removing redundant or less critical sequences, the patent achieves high expression with compressed regulatory element lengths that fit within vector capacity.
Solution Approach 2:
The patent creates composite regulatory elements by combining multiple short, highly active functional modules (promoter fragments, enhancer elements, UTR sequences, intronic regions) into a compact composite structure. This composite approach achieves synergistic expression enhancement while maintaining a total length suitable for vector packaging.
3Reliability
If large transgenes are constructed to achieve therapeutic efficacy, then therapeutic effectiveness improves, but vector packaging capacity is exceeded
Solution Approach 1:
The patent optimizes transgene construction parameters including coding sequence compression, removal of introns where appropriate, and optimization of open reading frames to maximize protein yield per base pair. Combined with optimized regulatory elements, this allows therapeutic doses of protein to be achieved with smaller transgene sizes that fit within vector capacity.
Solution Approach 2:
The patent uses highly efficient regulatory elements that act as powerful 'copying' or amplification mechanisms, where a small regulatory sequence drives the production of large amounts of therapeutic protein. This allows the transgene size to remain small while achieving high therapeutic effectiveness through enhanced expression levels.
Data Source
AI summary
Provided herein are compositions and methods for driving high expression of a transgene. Compositions and methods for driving high expression of a transgene comprising one or more human-derived regulatory elements, which, when operably linked to a transgene, can result in high expression of the transgene in one or more cell types or tissues.